Metronomic Oral Vinorelbine in Advanced Breast Cancer and Non-Small-Cell Lung Cancer: Current Status and Future Development
Marina Elena Cazzaniga(Azienda Ospedaliera San Gerardo), Guido Bocci(University of Pisa), Elisabetta Munzone(Istituti di Ricovero e Cura a Carattere Scientifico), Felice Pasini(Ospedale Civile Di Ivrea), Andrea Camerini(Ospedale Versilia), Franco Nolè(European Institute of Oncology), Paola Papaldo(Cancer Institute (WIA)), Alessandro Del Conte(University of Catania), Raffaele Addeo(George Moore Community Clinic), Elena Collovà(Aziende Socio Sanitarie Territoriale Ovest Milanese), Manlio Mencoboni(Villa Torri Hospital), Silvana Saracchini(Centro di Riferimento Oncologico)
Cited by 54
Related Papers
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2019|617
Ductal Lavage for Detection of Cellular Atypia in Women at High Risk for Breast Cancer
|JNCI Journal of the National Cancer Institute|2001|275
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268